1. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297:813–9.
Article
2. Lyrio LD, Grassi MF, Santana IU, Olavarria VG, Gomes Ado N, CostaPinto L, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013; 33:335–40.
Article
3. Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatol Ther. 2010; 23:458–76.
Article
4. Lee YH, Choe JY, Park SH, Park YW, Lee SS, Kang YM, et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci. 2010; 25:1431–7.
Article
5. Klumb EM, Pinto AC, Jesus GR, Araujo M Jr, Jascone L, Gayer CR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010; 19:1485–91.
Article
6. Ornstein A, Hatchette T. Human papillomavirus and anogenital warts in children. CMAJ. 2012; 184:321.
Article
7. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157:218–26.
Article
8. Nicholls PK, Stanley MA. The immunology of animal papillomaviruses. Vet Immunol Immunopathol. 2000; 73:101–27.
Article
9. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005; 38:473–85.
Article
10. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356:1928–43.
Article
11. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367:1247–55.
Article
12. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an in-terim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369:2161–70.
Article
13. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013; 72:659–64.
Article
14. Santana IU, Gomes Ado N, Lyrio LD, Rios Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011; 30:665–72.
Article
15. Febronio MV, Pereira RM, Bonfa E, Takiuti AD, Pereyra EA, Silva CA. Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus. 2007; 16:430–5.
Article